CY1121419T1 - Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης - Google Patents
Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζηςInfo
- Publication number
- CY1121419T1 CY1121419T1 CY20191100218T CY191100218T CY1121419T1 CY 1121419 T1 CY1121419 T1 CY 1121419T1 CY 20191100218 T CY20191100218 T CY 20191100218T CY 191100218 T CY191100218 T CY 191100218T CY 1121419 T1 CY1121419 T1 CY 1121419T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vivo
- proteins
- fucosyling
- fucocze
- proportions
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000008267 fucoses Chemical class 0.000 abstract 1
- 230000033581 fucosylation Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση προβλέπει μεθόδους και συνθέσεις για την αναστολή της φουκοσυλίωσης των πρωτεϊνών, συμπεριλαμβανομένων των αντισωμάτων, in vivo με τη χορήγηση ενός αναλόγου φουκόζης.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37111610P | 2010-08-05 | 2010-08-05 | |
PCT/US2011/046857 WO2012019165A2 (en) | 2010-08-05 | 2011-08-05 | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121419T1 true CY1121419T1 (el) | 2020-05-29 |
Family
ID=45560106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100218T CY1121419T1 (el) | 2010-08-05 | 2019-02-20 | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης |
Country Status (21)
Country | Link |
---|---|
US (4) | US9504702B2 (el) |
EP (2) | EP2608796B1 (el) |
JP (4) | JP5918235B2 (el) |
KR (2) | KR101950520B1 (el) |
CN (2) | CN103402525B (el) |
AU (3) | AU2011285490B2 (el) |
CA (1) | CA2803388C (el) |
CY (1) | CY1121419T1 (el) |
DK (1) | DK2608796T3 (el) |
ES (1) | ES2711622T3 (el) |
HU (1) | HUE043370T2 (el) |
IL (2) | IL224487A (el) |
MX (1) | MX356671B (el) |
NZ (1) | NZ606250A (el) |
PL (1) | PL2608796T3 (el) |
PT (1) | PT2608796T (el) |
RU (2) | RU2625768C2 (el) |
SI (1) | SI2608796T1 (el) |
TR (1) | TR201902439T4 (el) |
WO (1) | WO2012019165A2 (el) |
ZA (1) | ZA201300653B (el) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
EP2608796B1 (en) * | 2010-08-05 | 2018-11-21 | Seattle Genetics, Inc. | Inhibition of protein fucosylation in vivo using fucose analogs |
MX363385B (es) * | 2012-08-23 | 2019-03-20 | Seattle Genetics Inc | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. |
US9328134B2 (en) | 2013-02-22 | 2016-05-03 | Amgen Inc. | Carbohydrate phosphonate derivatives as modulators of glycosylation |
CN106699886A (zh) * | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
JP6906520B2 (ja) * | 2015-12-04 | 2021-07-21 | シージェン インコーポレイテッド | チェックポイント阻害剤と組みわせて2−デオキシ−2−フルオロ−l−フコースを用いる癌治療 |
US11118208B2 (en) | 2016-05-10 | 2021-09-14 | Ares Trading S.A. | Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose |
JP2018002666A (ja) * | 2016-07-04 | 2018-01-11 | 国立研究開発法人理化学研究所 | フコース類似体と糖を検出する方法 |
US11891644B2 (en) * | 2017-06-07 | 2024-02-06 | Seagen Inc. | T cells with reduced surface fucosylation and methods of making and using the same |
AU2018375331A1 (en) | 2017-12-01 | 2020-05-14 | Pfizer Inc. | Anti-CXCR5 antibodies and compositions and uses thereof |
SG11202009539XA (en) | 2018-03-29 | 2020-10-29 | Pfizer | Lfa3 variants and compositions and uses thereof |
JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗tigit抗体 |
JP7446587B2 (ja) | 2018-12-27 | 2024-03-12 | 慶應義塾 | 抗ヒトノロウイルス剤 |
KR20220115998A (ko) * | 2019-12-19 | 2022-08-19 | 메르크 파텐트 게엠베하 | 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물 |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
JP2023528400A (ja) * | 2020-06-03 | 2023-07-04 | サイモン フレイザー ユニヴァーシティー | タンパク質フコシル化の阻害剤及びその用途 |
TW202317614A (zh) | 2021-06-07 | 2023-05-01 | 美商安進公司 | 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平 |
CN113413465B (zh) * | 2021-06-15 | 2022-06-03 | 北京大学 | 岩藻糖基化抑制剂在抗癌导致炎症中的应用 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440780A (en) | 1979-06-01 | 1984-04-03 | Chevron Research Company | Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones |
JPH0660189B2 (ja) | 1986-01-22 | 1994-08-10 | 財団法人微生物化学研究会 | 2,6−ジデオキシ−2−フルオロ−l−タロピラノ−ス又はその誘導体とその製造法 |
FR2630914A1 (fr) | 1988-05-04 | 1989-11-10 | Hoechst Sa Laboratoires | Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments |
KR100211417B1 (ko) | 1990-11-30 | 1999-10-01 | 유충식 | L-탈로피라노시드 유도체 및 그의 제조방법 |
US5461143A (en) | 1991-03-18 | 1995-10-24 | The Scripps Research Institute | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
US5210078A (en) | 1991-04-30 | 1993-05-11 | The Biomembrane Institute | Trifluoromethyl analogs of fucose and uses thereof |
EP0642526B1 (en) | 1991-10-15 | 1998-12-23 | The Scripps Research Institute | Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of gdp-fucose |
CA2172983A1 (en) | 1993-09-29 | 1995-04-06 | Kei Sugai | 21-substituted steroid compound |
US5481143A (en) | 1993-11-15 | 1996-01-02 | Burdick; Brian K. | Self starting brushless d.c. motor |
FR2723947B1 (fr) | 1994-08-31 | 1996-09-27 | Adir | Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE19524515A1 (de) | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharid-Konjugate |
US6713287B1 (en) | 1995-10-24 | 2004-03-30 | The Scripps Research Institute | Enzymatic synthesis of L-fucose and L-fucose analogs |
WO1998018805A2 (en) * | 1996-10-28 | 1998-05-07 | Novartis Ag | Sugar derivatives as sialyl lewis x mimetics |
US5770407A (en) | 1996-12-10 | 1998-06-23 | The Scripps Research Institute | Process for preparing nucleotide inhibitors of glycosyltransferases |
JP4451933B2 (ja) * | 1996-12-27 | 2010-04-14 | 住友化学株式会社 | 遺伝子操作による植物へのppo阻害性除草剤耐性付与法 |
US6075134A (en) | 1997-05-15 | 2000-06-13 | The Regents Of The University Of California | Glycoconjugates and methods |
JPH1135593A (ja) | 1997-07-18 | 1999-02-09 | Daikin Ind Ltd | 2−フルオロフコシル−n−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法 |
US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
CA2513399A1 (en) | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
CA2522345A1 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7691603B2 (en) | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US7332334B2 (en) | 2003-04-18 | 2008-02-19 | Oklahoma Medical Research Foundation | Hematopoietic stem cells treated by in vitro fucosylation and methods of use |
DE602004028249D1 (de) | 2003-06-18 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Fucosetransporter |
JPWO2005035741A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
KR20060129296A (ko) | 2003-12-23 | 2006-12-15 | 프로젠 인더스트리즈 리미티드 | 글리코사미노글리칸(gag) 모방체 |
DE102004032421A1 (de) | 2004-07-05 | 2006-01-26 | Bayer Cropscience Ag | Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate |
US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
EP2208783A1 (en) | 2004-12-22 | 2010-07-21 | Chugai Seiyaku Kabushiki Kaisha | Method of producing an antibody using a cell in which the function of fucose transporter is inhibited |
CA2605507C (en) | 2005-04-19 | 2016-06-28 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
US7700321B2 (en) | 2005-10-21 | 2010-04-20 | Genzyme Corporation | Antibody-based therapeutics with enhanced ADCC activity |
US8278349B2 (en) | 2005-11-28 | 2012-10-02 | Ramot At Tel-Aviv University Ltd. | Cancer treatment using FTS and 2-deoxyglucose |
CN101400793B (zh) * | 2005-12-21 | 2014-06-11 | 维文蒂阿生物技术股份有限公司 | 与癌症相关的新抗原 |
WO2007081031A1 (ja) | 2006-01-16 | 2007-07-19 | Hokkaido University | 糖転移酵素阻害剤 |
US20070249014A1 (en) | 2006-02-10 | 2007-10-25 | Invitrogen Corporation | Labeling and detection of post translationally modified proteins |
WO2007101148A2 (en) | 2006-02-24 | 2007-09-07 | Board Of Regents, The University Of Texas System | Hexose compounds to treat cancer |
EP1991056A4 (en) | 2006-02-24 | 2009-09-02 | Univ Miami | MANNOSEDERIVATES FOR THE KILLING OF TUMOR CELLS |
JP5885378B2 (ja) | 2006-03-22 | 2016-03-22 | ザ スクリプス リサーチ インスティテュート | グリコペプチドの調製法 |
US9149489B2 (en) | 2006-04-27 | 2015-10-06 | Board Of Regents, University Of Texas System | Inhibitors of glycolysis useful in the treatment of brain tumors |
WO2009108926A1 (en) | 2008-02-29 | 2009-09-03 | Board Of Regents, The University Of Texas System | Inhibitors of glycolysis useful in the treatment of brain tumors |
EP2076538A2 (en) | 2006-10-24 | 2009-07-08 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
CA2677747A1 (en) | 2007-02-09 | 2008-08-21 | Glycomimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
WO2008131024A1 (en) | 2007-04-17 | 2008-10-30 | Board Of Regents, The University Of Texas System | Iodo-hexose compounds useful to treat cancer |
CN101062939A (zh) | 2007-05-17 | 2007-10-31 | 北京热景生物技术有限公司 | 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒 |
SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
WO2009114641A1 (en) | 2008-03-11 | 2009-09-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
CA2723197C (en) * | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
WO2009143078A2 (en) | 2008-05-19 | 2009-11-26 | Board Of Regents, The University Of Texas System | Methods of treating brain cancer using hexose compounds |
EP2303282A4 (en) | 2008-05-23 | 2013-02-13 | Univ Miami | TREATMENT UTILIZING A LOW-DOSE CONTINUOUS APPLICATION OF SUGAR ANALOGS |
WO2010005735A2 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
US20120100609A1 (en) | 2009-03-27 | 2012-04-26 | Crawford Brett E | N-linked glycan biosynthesis modulators |
EP2566876A4 (en) * | 2010-05-06 | 2014-01-08 | Univ Fraser Simon | METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES |
US20110288880A1 (en) | 2010-05-07 | 2011-11-24 | Patient Care Automation Services, Inc. | Targeted health care messaging |
EP2608796B1 (en) * | 2010-08-05 | 2018-11-21 | Seattle Genetics, Inc. | Inhibition of protein fucosylation in vivo using fucose analogs |
CA2824175A1 (en) | 2011-01-11 | 2012-07-19 | The University Of Texas M.D. Anderson Cancer | Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases |
US8979675B2 (en) | 2012-04-25 | 2015-03-17 | Nike, Inc. | Golf ball core having radial appendages |
MX363385B (es) | 2012-08-23 | 2019-03-20 | Seattle Genetics Inc | Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias. |
JP6906520B2 (ja) | 2015-12-04 | 2021-07-21 | シージェン インコーポレイテッド | チェックポイント阻害剤と組みわせて2−デオキシ−2−フルオロ−l−フコースを用いる癌治療 |
-
2011
- 2011-08-05 EP EP11815404.6A patent/EP2608796B1/en active Active
- 2011-08-05 ES ES11815404T patent/ES2711622T3/es active Active
- 2011-08-05 CA CA2803388A patent/CA2803388C/en active Active
- 2011-08-05 MX MX2013001303A patent/MX356671B/es active IP Right Grant
- 2011-08-05 SI SI201131673T patent/SI2608796T1/sl unknown
- 2011-08-05 CN CN201180038334.2A patent/CN103402525B/zh active Active
- 2011-08-05 KR KR1020137005545A patent/KR101950520B1/ko active IP Right Grant
- 2011-08-05 DK DK11815404.6T patent/DK2608796T3/en active
- 2011-08-05 KR KR1020197004266A patent/KR20190022884A/ko not_active Application Discontinuation
- 2011-08-05 PL PL11815404T patent/PL2608796T3/pl unknown
- 2011-08-05 HU HUE11815404A patent/HUE043370T2/hu unknown
- 2011-08-05 JP JP2013523380A patent/JP5918235B2/ja active Active
- 2011-08-05 CN CN201710076003.7A patent/CN107007615A/zh active Pending
- 2011-08-05 US US13/814,083 patent/US9504702B2/en active Active
- 2011-08-05 AU AU2011285490A patent/AU2011285490B2/en active Active
- 2011-08-05 PT PT11815404T patent/PT2608796T/pt unknown
- 2011-08-05 NZ NZ606250A patent/NZ606250A/en unknown
- 2011-08-05 RU RU2013109415A patent/RU2625768C2/ru active
- 2011-08-05 WO PCT/US2011/046857 patent/WO2012019165A2/en active Application Filing
- 2011-08-05 RU RU2017122482A patent/RU2017122482A/ru not_active Application Discontinuation
- 2011-08-05 TR TR2019/02439T patent/TR201902439T4/tr unknown
- 2011-08-05 EP EP18206850.2A patent/EP3513794A3/en not_active Withdrawn
-
2013
- 2013-01-24 ZA ZA2013/00653A patent/ZA201300653B/en unknown
- 2013-01-30 IL IL224487A patent/IL224487A/en active IP Right Grant
-
2016
- 2016-02-08 IL IL244019A patent/IL244019B/en active IP Right Grant
- 2016-04-07 JP JP2016076930A patent/JP6113887B2/ja active Active
- 2016-06-29 AU AU2016204495A patent/AU2016204495A1/en not_active Abandoned
- 2016-10-21 US US15/299,894 patent/US10342811B2/en active Active
-
2017
- 2017-03-15 JP JP2017049534A patent/JP6622238B2/ja active Active
- 2017-12-20 AU AU2017279653A patent/AU2017279653A1/en not_active Abandoned
-
2019
- 2019-02-20 CY CY20191100218T patent/CY1121419T1/el unknown
- 2019-06-25 US US16/452,160 patent/US11033561B2/en active Active
- 2019-11-21 JP JP2019210313A patent/JP2020040974A/ja active Pending
-
2021
- 2021-05-07 US US17/315,144 patent/US20210260086A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121419T1 (el) | Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1122480T1 (el) | Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας | |
CY1121843T1 (el) | Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου | |
CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
CY1117479T1 (el) | Βενζοδιαζεπινικος αναστολεας bromodomain | |
CY1118906T1 (el) | Χαμηλης συγγενειας αντισωματα υποδοχεα αιματοεγκεφαλικου φραγμου και χρησεις αυτων | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CY1117650T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
CL2013003145A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un antioxidante o quelante y al menos un aminoácido libre. | |
EA201600495A1 (ru) | Пролекарство адреномедуллина на основе полиэтиленгликоля и его применение | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
EA201390804A1 (ru) | Лекарственная форма лакозамида для приема один раз в сутки | |
MY165002A (en) | Cylodextrin complexation methods for formulating peptide proteasome inhibitors | |
BR112013003722A2 (pt) | produtos para cuidado e métodos de uso e fabricação dos mesmos | |
UA118167C2 (uk) | Пептид та його застосування | |
UA111717C2 (uk) | Склад для перорального введення і ліпофільні солі метилналтрексону |